ES2084347T3 - Derivados de 5-heteroil-indol. - Google Patents

Derivados de 5-heteroil-indol.

Info

Publication number
ES2084347T3
ES2084347T3 ES92904837T ES92904837T ES2084347T3 ES 2084347 T3 ES2084347 T3 ES 2084347T3 ES 92904837 T ES92904837 T ES 92904837T ES 92904837 T ES92904837 T ES 92904837T ES 2084347 T3 ES2084347 T3 ES 2084347T3
Authority
ES
Spain
Prior art keywords
alkyl
hydrogen
heteroil
indol
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92904837T
Other languages
English (en)
Spanish (es)
Inventor
Jolanta Teresa Nowakowski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp Belgium
Pfizer Corp SRL
Original Assignee
Pfizer Corp Belgium
Pfizer Corp SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp Belgium, Pfizer Corp SRL filed Critical Pfizer Corp Belgium
Application granted granted Critical
Publication of ES2084347T3 publication Critical patent/ES2084347T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Luminescent Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
ES92904837T 1991-02-12 1992-02-03 Derivados de 5-heteroil-indol. Expired - Lifetime ES2084347T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65471291A 1991-02-12 1991-02-12

Publications (1)

Publication Number Publication Date
ES2084347T3 true ES2084347T3 (es) 1996-05-01

Family

ID=24625959

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92904837T Expired - Lifetime ES2084347T3 (es) 1991-02-12 1992-02-03 Derivados de 5-heteroil-indol.

Country Status (24)

Country Link
EP (1) EP0571471B1 (cg-RX-API-DMAC7.html)
JP (1) JPH07121942B2 (cg-RX-API-DMAC7.html)
KR (1) KR930703305A (cg-RX-API-DMAC7.html)
AT (1) ATE135005T1 (cg-RX-API-DMAC7.html)
AU (1) AU655456B2 (cg-RX-API-DMAC7.html)
CA (1) CA2101521A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ165693A3 (cg-RX-API-DMAC7.html)
DE (1) DE69208868T2 (cg-RX-API-DMAC7.html)
DK (1) DK0571471T3 (cg-RX-API-DMAC7.html)
ES (1) ES2084347T3 (cg-RX-API-DMAC7.html)
FI (1) FI933551A0 (cg-RX-API-DMAC7.html)
GR (1) GR3019778T3 (cg-RX-API-DMAC7.html)
HU (1) HUT65766A (cg-RX-API-DMAC7.html)
IE (1) IE920442A1 (cg-RX-API-DMAC7.html)
IL (1) IL100888A0 (cg-RX-API-DMAC7.html)
MX (1) MX9200569A (cg-RX-API-DMAC7.html)
MY (1) MY131298A (cg-RX-API-DMAC7.html)
NO (1) NO932859L (cg-RX-API-DMAC7.html)
NZ (1) NZ241584A (cg-RX-API-DMAC7.html)
PT (1) PT100114A (cg-RX-API-DMAC7.html)
TW (1) TW263508B (cg-RX-API-DMAC7.html)
WO (1) WO1992013856A1 (cg-RX-API-DMAC7.html)
YU (1) YU13792A (cg-RX-API-DMAC7.html)
ZA (1) ZA92969B (cg-RX-API-DMAC7.html)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW288010B (cg-RX-API-DMAC7.html) * 1992-03-05 1996-10-11 Pfizer
PL172405B1 (en) * 1992-04-07 1997-09-30 Pfizer Derivatives of indole
GB9211277D0 (en) 1992-05-28 1992-07-15 Glaxo Group Inc Pharmaceutical compositions
GB9226537D0 (en) * 1992-12-21 1993-02-17 Smithkline Beecham Plc Compounds
GB9226532D0 (en) * 1992-12-21 1993-02-17 Smithkline Beecham Plc Compounds
ES2070087B1 (es) * 1993-08-13 1996-02-16 Pfizer Derivados de indol
US6423731B2 (en) 1994-01-06 2002-07-23 Zeneca Limited Indole derivatives as prodrugs of 5-HT1-like receptor agonists
US5468768A (en) * 1994-01-06 1995-11-21 Bristol-Myers Squibb Company Antimigraine derivatives of indolylcycloalkanylamines
JPH10501212A (ja) * 1994-05-19 1998-02-03 メルク シヤープ エンド ドーム リミテツド 5−ht▲下1d▼−アルファ作働薬としてのインドール−3−イルアルキルのピペラジン、ピペリジンおよびテトラヒドロピリジン誘導体
DE69521895T2 (de) * 1994-06-01 2002-04-04 Astrazeneca Ab, Soedertaelje Indolderivate als prodrugs von "5-ht1-like" rezeptor agonisten
US5521196A (en) * 1994-10-05 1996-05-28 Eli Lilly And Company 5-HT1F agonists for the treatment of migraine
US5521197A (en) * 1994-12-01 1996-05-28 Eli Lilly And Company 3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT1F agonists
GB9501865D0 (en) * 1995-01-31 1995-03-22 Merck Sharp & Dohme Therapeutic agents
TR199700993T1 (xx) * 1995-03-20 1998-03-21 Eli Lilly And Company 5-ikameli-3-(1,2,3,6-tetrahidropridin-4-il)- ve 3-(piperidin-4-il)-1H-indoller: yeni 5-HT1F agonistler.
JPH11513666A (ja) * 1995-10-10 1999-11-24 イーライ・リリー・アンド・カンパニー N−[2−置換−3−(2−アミノエチル)−1h−インドール−5−イル]−アミド:新規5−ht▲下1f▼作動剤
GB9523583D0 (en) * 1995-11-17 1996-01-17 Merck Sharp & Dohme Therapeutic agents
FR2754709B1 (fr) 1996-10-23 1999-03-05 Sanofi Sa Composition cosmetique contenant un antagoniste des recepteurs du neuropeptide gamma et alpha 2 antagonistes susceptibles d'etre incorpores dans une telle composition
FR2763243A1 (fr) * 1997-05-14 1998-11-20 Pf Medicament Utilisation d'amines indoliques comme medicaments antithrombotiques
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
DK1068198T3 (da) * 1998-03-09 2003-09-22 Lundbeck & Co As H 5-Heteroarylsubstituerede indoler
JP2002519348A (ja) 1998-06-30 2002-07-02 イーライ・リリー・アンド・カンパニー 5−ht1fアゴニスト
CA2370147C (en) * 1999-04-21 2009-07-28 Allelix Biopharmaceuticals Inc. Piperidine-indole compounds having 5-ht6 affinity
WO2001034146A1 (en) * 1999-11-08 2001-05-17 Smithkline Beecham Corporation Novel anti-infectives
CA2422717A1 (en) * 2000-10-20 2002-04-25 Biovitrum Ab 2-, 3-, 4-, or 5-substituted-n1-(benzensulfonyl)indoles and their use in therapy
DE10121217A1 (de) 2001-04-30 2002-10-31 Merck Patent Gmbh 6H-Oxazolo[4,5-e]indol-Derivate als nikotinische Acetylcholinrezeptor Liganden und/oder serotonerge Liganden
US7008958B2 (en) 2002-05-21 2006-03-07 Bristol-Myers Squibb Company 2-substituted 5-oxazolyl indole compounds useful as IMPDH inhibitors and pharmaceutical compositions comprising same
MXPA05005701A (es) 2002-11-28 2005-08-16 Suven Life Sciences Ltd N-arilsulfonil indoles sustituidos en la posicion 3 que tienen afinidad por el receptor de la serotonina, proceso para su preparacion y composiciones farmaceuticas que los contienen.
US7332508B2 (en) 2002-12-18 2008-02-19 Novo Nordisk A/S Substituted homopiperidine, piperidine or pyrrolidine derivatives
WO2005005439A1 (en) * 2003-07-09 2005-01-20 Suven Life Sciences Limited Benzothiazino indoles
US20050245540A1 (en) * 2003-12-09 2005-11-03 Fujisawa Pharmaceutical Co., Ltd. New methods
WO2005121132A1 (ja) * 2004-06-11 2005-12-22 Shionogi & Co., Ltd. 抗hcv作用を有する縮合ヘテロ環化合物
SI1883451T1 (sl) 2005-04-13 2011-04-29 Neuraxon Inc Substituirane indolne spojine z NOS inhibitorno aktivnostjo
EA016300B1 (ru) * 2005-07-29 2012-04-30 4ЭсЦэ АГ НОВЫЕ ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ NF-κB
WO2007098418A1 (en) * 2006-02-17 2007-08-30 Memory Pharmaceuticals Corporation Compounds having 5-ht6 receptor affinity
EP2010527B1 (en) 2006-04-13 2013-08-14 Neuraxon Inc. 1,5 and 3,6- substituted indole compounds having nos inhibitory activity
US20100222345A1 (en) * 2006-08-09 2010-09-02 Caroline Jean Diaz Novel compounds as antagonists or inverse agonists for opioid receptors
TW200848021A (en) 2007-03-06 2008-12-16 Wyeth Corp Sulfonylated heterocycles useful for modulation of the progesterone receptor
KR20100103799A (ko) 2007-11-16 2010-09-28 네우렉슨 인코포레이티드 내장통을 치료하기 위한 인돌 화합물 및 방법
WO2012064744A2 (en) * 2010-11-08 2012-05-18 Lycera Corporation Tetrahydroquinoline and related bicyclic compounds for inhibition of rorϒ activity and the treatment of disease
AU2013259737A1 (en) 2012-05-08 2014-10-02 Lycera Corporation Tetrahydronaphthyridine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease
JP6242868B2 (ja) 2012-05-08 2017-12-06 リセラ・コーポレイションLycera Corporation RORγのアゴニストとしての使用のためおよび疾患の処置のためのテトラヒドロ[1,8]ナフチリジンスルホンアミドおよび関連化合物
WO2015095795A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. TETRAHYDRONAPHTHYRIDINE, BENZOXAZINE, AZA-BENZOXAZINE, AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
US9783511B2 (en) 2013-12-20 2017-10-10 Lycera Corporation Carbamate benzoxazine propionic acids and acid derivatives for modulation of RORgamma activity and the treatment of disease
US9663502B2 (en) 2013-12-20 2017-05-30 Lycera Corporation 2-Acylamidomethyl and sulfonylamidomethyl benzoxazine carbamates for inhibition of RORgamma activity and the treatment of disease
EP3110429A4 (en) 2014-02-27 2018-02-21 Lycera Corporation Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma & related therapeutic methods
EP3140291A4 (en) 2014-05-05 2018-01-10 Lycera Corporation Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
WO2015171558A2 (en) 2014-05-05 2015-11-12 Lycera Corporation BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE
EP3256450B1 (en) 2015-02-11 2020-12-02 Merck Sharp & Dohme Corp. Substituted pyrazole compounds as ror-gamma-t inhibitors and uses thereof
JP2018515491A (ja) 2015-05-05 2018-06-14 リセラ・コーポレイションLycera Corporation RORγの作動薬及び疾患の療法として使用するジヒドロ−2H−ベンゾ[b][1,4]オキサジンスルホンアミド及び関連化合物
MX2017016134A (es) 2015-06-11 2018-08-15 Lycera Corp Aril dihidro-2h-benzo[b][1,4]oxazina sulfonamida y compuestos relacionados para uso como agonistas de rory y el tratamiento de enfermedad.
WO2017075185A1 (en) 2015-10-27 2017-05-04 Merck Sharp & Dohme Corp. Heteroaryl substituted benzoic acids as rorgammat inhibitors and uses thereof
US10287272B2 (en) 2015-10-27 2019-05-14 Merck Sharp & Dohme Corp. Substituted indazole compounds as RORgammaT inhibitors and uses thereof
US10344000B2 (en) 2015-10-27 2019-07-09 Merck Sharp & Dohme Corp. Substituted bicyclic pyrazole compounds as RORgammaT inhibitors and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8332437D0 (en) * 1983-12-06 1984-01-11 Glaxo Group Ltd Chemical compounds
EP0225726B1 (en) * 1985-11-08 1991-04-17 Glaxo Group Limited Indole derivatives
GB8600398D0 (en) * 1986-01-08 1986-02-12 Glaxo Group Ltd Chemical compounds
GB8719167D0 (en) * 1987-08-13 1987-09-23 Glaxo Group Ltd Chemical compounds
GB8724912D0 (en) * 1987-10-23 1987-11-25 Wellcome Found Indole derivatives
US5399574A (en) * 1990-06-07 1995-03-21 Burroughs Wellcome Co. Indolyl tetrahydropyridines for treating migraine

Also Published As

Publication number Publication date
MY131298A (en) 2007-08-30
FI933551A7 (fi) 1993-08-11
ZA92969B (en) 1993-08-11
DK0571471T3 (da) 1996-04-01
NO932859D0 (no) 1993-08-11
PT100114A (pt) 1993-05-31
CA2101521A1 (en) 1992-08-13
DE69208868T2 (de) 1996-10-17
NO932859L (no) 1993-08-11
IE920442A1 (en) 1992-08-12
FI933551L (fi) 1993-08-11
JPH06500122A (ja) 1994-01-06
AU1263792A (en) 1992-09-07
NZ241584A (en) 1994-12-22
JPH07121942B2 (ja) 1995-12-25
IL100888A0 (en) 1992-11-15
WO1992013856A1 (en) 1992-08-20
ATE135005T1 (de) 1996-03-15
GR3019778T3 (en) 1996-07-31
EP0571471B1 (en) 1996-03-06
HUT65766A (en) 1994-07-28
HU9302328D0 (en) 1993-10-28
KR930703305A (ko) 1993-11-29
CZ165693A3 (en) 1994-05-18
EP0571471A1 (en) 1993-12-01
YU13792A (sh) 1994-11-15
FI933551A0 (fi) 1993-08-11
AU655456B2 (en) 1994-12-22
TW263508B (cg-RX-API-DMAC7.html) 1995-11-21
DE69208868D1 (de) 1996-04-11
MX9200569A (es) 1992-08-01

Similar Documents

Publication Publication Date Title
ES2084347T3 (es) Derivados de 5-heteroil-indol.
ES8603711A1 (es) Procedimiento para preparar compuestos benzimidazoles 2-piridilmetil-tio y sulfinil substituidos
ES2066991T3 (es) Agentes hipoglucemiantes de oxazolidinadiona.
ES8501754A1 (es) &#34;un metodo de preparacion de nuevas sulfonamidas sustituidas&#34; nota: se solicita como divisional de la patente de invencion n 516.504.
ATE31307T1 (de) Benzofuran- und benzopyrancarboxamid-derivate.
PL216409A1 (cg-RX-API-DMAC7.html)
NZ332559A (en) 3-mercapto-propylamine substituted 4-carbonylamino-5,5-dimethyl-thiazolidine derivatives
DE69728544D1 (de) Totalsynthese von acylfulvenen mit antitumorwirkung
ATE237612T1 (de) Benzofuranderivate
NZ528997A (en) Sulfonamides
DK429089D0 (da) Alkylbenzylaminer
UY24010A1 (es) Nuevos pirrolocarbazoles
ES2064618T3 (es) Agonistas de serotonina de tetrahidrobenz(c,d)indol.
DK0677042T3 (da) Selektive ligander af 5HT1D-5HT1B-receptorer, der er afledt af indolpiperazin og er nyttige som lægemidler
FI834730A0 (fi) 1-karboxialkanoylperhydro-indol-2-karboxylsyror och deras derivat
NO902336D0 (no) Antispasmotiske midler.
AR247735A1 (es) Sulfonildiamidas sustituidas, procedimientos para su preparacion, intermediarios utilizados en el procedimiento, y su utilizacion como herbicidas y reguladoras del crecimiento de las plantas
PT87048A (pt) Process for preparing benzazepine sulfonamides antiarrhythmic agents
CO4410332A1 (es) Oxazoles y tiazoles sustituidos
GR1001309B (el) Μεθοδος παρασκευης παραγωγου ενωσεως της διχλωροανιλινης.
ATE41149T1 (de) Substituierte furazane.
US4010175A (en) Thio-{62 -lactam penicillins
ES2097319T3 (es) Derivados de isoxazol como agentes protectores de la luz.
ECSP951529A (es) Compuestos farmaceuticos
ATE130616T1 (de) Stabiles hexahydrat von etoposid-4&#39;-phosphat- dinatriumsalz.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 571471

Country of ref document: ES